Climb Bio to present ITP drug data at ASH meeting in December
Tweet Send to a Friend
Climb Bio, Inc. (Nasdaq: CLYM) announced it will present clinical data for its drug candidate budoprutug in immune thrombocytopenia (ITP) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




